Abstract: The present invention provides novel CD3 antigen binding fragments with particularly advantageous properties such as producibility, stability, binding affinity, biological activity, specific targeting of certain T cells, targeting efficiency, remaining tumor cell killing and reduced toxicity. The present invention also provides bispecific antigen binding molecules for activating T cells. In addition, the invention further provides methods of treating cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising the above said bispecific antigen binding molecules.

Abstract: The Differential Shock Absorbing High Heel Foot Insole System is a differential shock absorption system designed to effectively absorb the shock while providing the comfort to the wearer of the high heels, especially the highest ones. The system provides an effective solution minimize the excruciating pain being felt when wearing high heels, especially the highest ones. The pain felt is a result to the repeated shocks experienced by a very small area of the underfoot each time the human foot undergoes a step in high heels. Differential Shock Absorbing High Heel Foot Insole System takes into account a correct estimation of the materials compression force deflection and peak deceleration properties, providing the correct level of shock absorption required parameters, plus the added cushioning effect for comfort of the wearer, which are crucial in the material selection to absorb the shocks when wearing high heels, something which other products out on the market and/or solutions proposed are lacking of.

Abstract: The inventors developed novel pseudotyped lentiviral vector particles comprising a morbillivirus fusion (F) protein and a mutated hemagglutinin (H) protein of the measles virus (MeV) or the Edmonton strain of the measles virus (MeVEdm), wherein the cytoplasmic portions of the F and the H protein are truncated, and wherein the amino acids necessary for receptor recognition in the H protein are mutated that it does not interact with CD46, SLAM and/or nectin-4 and further has a single chain antibody to a cell surface marker of hESCs and iPSCs at its ectodomain. In this invention, the single chain variable fragment (scFv) anti-cell surface marker coding sequence of the single chain antibody is fused to the coding sequence at the ectodomain of the H protein, wherein the single chain antibody is selected from the group consisting of CD30, EpCAM (CD326), CD9, Thy-1 (CD90), SSEA-3, SSEA-4, TRA-1-60 or TRA-1-81. The transduction according to the present invention does not interfere with the pluripotency, i.e.

Abstract: The invention relates to a method for identifying stabilizing amino acids in single chain antibody fragments.